Thursday, 6 June, 12h30, MSG-025 MSSI Building

Osentia®:  A Novel Screening Tool for Fracture Risk


Osentia® is sold online ( and through selected UK-based pharmacies. OsentiaÒ, invented by Mark Towler, exploits a patented algorithm that combines information around a subject’s protein structure with their clinical risk factors to determine relative risk of fracture.

This presentation will consider how OsentiaÒ originated from basic research in Towler’s laboratory through its development in clinical trials emerging as a screening tool launched for over the counter testing in 2016.


Mark Towler is Professor in the Department of Mechanical and Industrial Engineering at Ryerson University with a cross-appointment in St. Michael’s Hospital, both in Toronto, Canada. He moved to Canada in 2013, having previously worked in the University of Limerick, Alfred University (USA) and University Malaya (Malaysia). He holds a PhD in Biomaterials from Queen Mary College (London, UK).

Mark has generated over $25m funding to sustain active research programs on glass-based medical devices and in-vitro diagnostics. He has published 160 papers in the peer reviewed literature and invented/co-invented five granted patents.  He is the co-founder of two healthcare spin outs – Crescent Ops & Solas Diagnostics. He has supervised 16 PhD and 17 MSc theses to completion and mentored 18 post-doctoral fellows.  He currently supervises ten graduate students and mentors two post-doctoral fellows who are working on projects in the orthopaedics, cardiac and trauma fields.

 As Principal Investigator and leader of Ryerson’s Clinical Materials and Diagnostics group (, he holds ~C$3M active funding from the Canadian Institute of Health Research (CIHR) and the National Science and Engineering Research Council (NSERC).

Tea/coffee will be available at 12h15

For further information, please contact: